In depth reporting at STAT on the development of Bharat Biotech's Covaxin

"Protocols were not in public domain while the trials were happening, and the trials were happening at breakneck speed with no information about the basis for granting approvals,” said Aisola, adding that the handling of the adverse event also set a poor tone for investigating and sharing information with the public. “This isn’t just a purely scientific issue. It involves the role of the government and its partner, which was more than happy to cooperate, because it benefited as well.”

https://www.statnews.com/2022/11/15/vaccine-covid19-india-bharat-covaxin-transparency-protocols/